It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The molecular mechanisms that govern differential T cell development from CD4+CD25-conventional T (Tconv) into CD4+CD25+ forkhead-box-P3+ (FoxP3+) inducible regulatory T (iTreg) cells remain unclear. Herein, we investigated the relative contribution of protein kinase A (PKA) in this process. Mechanistically, we found that PKA controlled the efficiency of human iTreg cell generation through the expression of different FoxP3 splicing variants containing or not the exon 2. We found that transient PKA inhibition reduced the recruitment of cAMP-responsive element-binding protein (CREB) on regulatory regions of the FoxP3 gene, a condition that is associated with an impaired acquisition of their suppressive capacity in vitro. To corroborate our findings in a human model of autoimmunity, we measured CREB phosphorylation and FoxP3 levels in iTreg cells from treatment-naïve relapsing–remitting (RR)-multiple sclerosis (MS) subjects. Interestingly, both phospho-CREB and FoxP3 induction directly correlated and were significantly reduced in RR-MS patients, suggesting a previously unknown mechanism involved in the induction and function of human iTreg cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Istituto per l’Endocrinologia e l’Oncologia Sperimentale “G. Salvatore”, Consiglio Nazionale delle Ricerche, Laboratorio di Immunologia, Naples, Italy (GRID:grid.429047.c) (ISNI:0000 0004 6477 0469)
2 Istituto per l’Endocrinologia e l’Oncologia Sperimentale “G. Salvatore”, Consiglio Nazionale delle Ricerche, Laboratorio di Immunologia, Naples, Italy (GRID:grid.429047.c) (ISNI:0000 0004 6477 0469); Università degli Studi di Napoli “Federico II”, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)
3 Istituto per l’Endocrinologia e l’Oncologia Sperimentale “G. Salvatore”, Consiglio Nazionale delle Ricerche, Laboratorio di Immunologia, Naples, Italy (GRID:grid.429047.c) (ISNI:0000 0004 6477 0469); IRCCS Fondazione Santa Lucia, Unità di Neuroimmunologia, Rome, Italy (GRID:grid.417778.a) (ISNI:0000 0001 0692 3437)
4 UOC di Medicina Trasfusionale, AORN Ospedale dei Colli, Ospedale Monaldi, Naples, Italy (GRID:grid.416052.4) (ISNI:0000 0004 1755 4122)
5 Università degli Studi di Napoli “Federico II”, Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)
6 Centro Regionale Sclerosi Multipla, Azienda Ospedaliera “A. Cardarelli”, Dipartimento di Neurologia, Naples, Italy (GRID:grid.413172.2)
7 Università degli Studi di Napoli “Federico II”, Dipartimento di Biologia, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)